Clinically, this entails improved screening protocols (e.g., annual cardiovascular risk assessment beginning at diabetes diagnosis) and broader access to cardioprotective therapies, such as subsidizing SGLT2is or GLP‐1 RAs for underserved populations through insurance reforms or voucher programs. The gene discussed is GLP1R; the disease is diabetes mellitus.